Validation of Strasbourg Environmental Exposure Chamber ALYATEC in Mite Allergic Subjects With Asthma

Inclusion Criteria: * Subjects having signed the informed consent * Subjects affiliated to a social security scheme * Positive metacholine test * FEV1 value \> 70% of theoretical FEV1 value * Asthma Control Test (ACT) ≥ 20/25 in 4 weeks prior to EEC exposure Group A: * Mild allergic asthma to HDM (GINA 1 or 2) with associated rhinitis and/or conjunctivitis. * Positive skin prick-test to Dpt and Df (wheal diameter \>5 mm compared to the negative control) * Specific immunoglobulin E (IgE) for Dpt and Df \> 0.7 kU/L Group B: * Mild allergic asthma (GINA 1 or 2) not sensitized to HDM with associated rhinitis and/or conjunctivitis. * Negative skin prick-test and specific IgE for Dpt and Df. * Positive skin prick-test and specific IgE for another allergen. Exclusion Criteria: * Uncontrolled asthma * Asthma Control Test (ACT) \< 20/25 in 4 weeks prior to EEC exposure * Use of oral corticosteroids in the 4 weeks preceding inclusion in the study * Use of biotherapy in the 4 months preceding inclusion in the study * Existence of a severe obstructive syndrome with FEV1 \<70% of the theoretical value * Obstruction triggered by spirometric evaluations * Hospitalization for asthma or exacerbation in the last 4 weeks * History of Acute Severe Asthma requiring hospitalization in intensive care or intubation * Desensitization to dust mite allergens in the last 5 years * Sensitization to allergens in the indoor environment (cat allergens or molds) with obvious exposure to these allergens * Active tobacco: plus 10 cigarettes / day and tobacco history of +10 PA * Uncontrolled systemic arterial hypertension * Recent myocardial infarction (\<3 months) * Recent stroke (\<3 months) * Known arterial aneurysm * Epilepsy under treatment * Progressive tumor pathology * Chronic renal pathology * Hypersensitivity to one of the excipients used * Subjects who participated in another clinical study in the three months prior to inclusion